BioCryst Pharmaceuticals Competitors

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares BioCryst Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Volatility & Risk

BioCryst Pharmaceuticals has a beta of 3.03, suggesting that its stock price is 203% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and Amgen's top-line revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for BioCryst Pharmaceuticals and Amgen, as provided by MarketBeat.

BioCryst Pharmaceuticals presently has a consensus price target of $11.3750, suggesting a potential upside of 4.17%. Amgen has a consensus price target of $257.3043, suggesting a potential upside of 15.95%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than BioCryst Pharmaceuticals.

Summary

Amgen beats BioCryst Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Profitability

This table compares BioCryst Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for BioCryst Pharmaceuticals and Gilead Sciences, as provided by MarketBeat.

BioCryst Pharmaceuticals currently has a consensus price target of $11.3750, indicating a potential upside of 4.17%. Gilead Sciences has a consensus price target of $96.0370, indicating a potential upside of 51.89%. Given Gilead Sciences' higher possible upside, analysts clearly believe Gilead Sciences is more favorable than BioCryst Pharmaceuticals.

Institutional & Insider Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares BioCryst Pharmaceuticals and Gilead Sciences' revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

BioCryst Pharmaceuticals has a beta of 3.03, meaning that its share price is 203% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Summary

Gilead Sciences beats BioCryst Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vertex Pharmaceuticals and BioCryst Pharmaceuticals, as reported by MarketBeat.

Vertex Pharmaceuticals currently has a consensus price target of $292.68, indicating a potential upside of 40.85%. BioCryst Pharmaceuticals has a consensus price target of $11.3750, indicating a potential upside of 4.17%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than BioCryst Pharmaceuticals.

Profitability

This table compares Vertex Pharmaceuticals and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Vertex Pharmaceuticals and BioCryst Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 3.03, meaning that its share price is 203% more volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats BioCryst Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BioCryst Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

BioCryst Pharmaceuticals presently has a consensus target price of $11.3750, indicating a potential upside of 4.17%. Regeneron Pharmaceuticals has a consensus target price of $625.8077, indicating a potential upside of 39.26%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than BioCryst Pharmaceuticals.

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and Regeneron Pharmaceuticals' gross revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioCryst Pharmaceuticals has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Profitability

This table compares BioCryst Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Insider and Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats BioCryst Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Biogen and BioCryst Pharmaceuticals, as provided by MarketBeat.com.

Biogen currently has a consensus price target of $304.4667, indicating a potential upside of 15.52%. BioCryst Pharmaceuticals has a consensus price target of $11.3750, indicating a potential upside of 4.17%. Given Biogen's higher probable upside, equities research analysts plainly believe Biogen is more favorable than BioCryst Pharmaceuticals.

Volatility & Risk

Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500.

Valuation & Earnings

This table compares Biogen and BioCryst Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biogen and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

83.5% of Biogen shares are held by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by insiders. Comparatively, 4.3% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Biogen beats BioCryst Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares BioCryst Pharmaceuticals and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BioCryst Pharmaceuticals has a beta of 3.03, indicating that its share price is 203% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for BioCryst Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.com.

BioCryst Pharmaceuticals currently has a consensus price target of $11.3750, suggesting a potential upside of 4.17%. Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential upside of 3.14%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares BioCryst Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Alexion Pharmaceuticals beats BioCryst Pharmaceuticals on 9 of the 15 factors compared between the two stocks.